Assay Screening Method Promises Auto-Immune Treatment

SLAS (Society for Laboratory Automation and Screening)

Oak Brook, IL (January 27, 2022) – The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.

This month’s featured article, “A high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of the antigen aminopeptidase ERAP1,” by Müller, et al, presents a newly developed matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) drug discovery assay for the endoplasmic reticulum aminopeptidase 1 (ERAP1). The dysregulation of ERAP1 has been associated with various auto-immune and auto-inflammatory diseases, making ERAP1 a high-profile target in drug discovery.

The research team behind this study utilized an existing ERAP1 RapidFire MS (RF MS) assay on which to base their MALDI-TOF assay, producing greater assay stability, reproducibility and robustness for the MALDI-TOF platform. When results were compared between the pre-established RF MS and the MALDI-TOF platforms, shorter sample cycle times, reduced reagent consumption and a lower tight-binding limit were all advantages of the MALDI-TOF platform.

Read this original research article to learn how the MALDI-TOF platform may detect other difficult targets, along with more research articles in the January issue of SLAS Discovery.

The January issue of SLAS Discovery includes these additional articles:

Access to the January issue of SLAS Discovery is available at

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.